MOUNTAIN VIEW, Calif., May 16, 2012 /PRNewswire/ -- Although there are approximately 27 drugs on the market indicated for the treatment of breast cancer, there is currently an unmet need to treat patients. Consequently, there are abounding opportunities for pharmaceutical manufacturers, as breast cancer is the second most common cancer among women. There are currently 55 breast cancer therapeutic drugs in the developmental phase in the U.S., with additional drugs expected to enter this stage in the years to come.
New analysis from Frost & Sullivan’s (http://www.pharma.frost.com) A Product and Pipeline Analysis of the U.S. Breast Cancer Therapeutics Market research highlights the current market landscape, providing a competitive analysis of all marketed and pipeline drugs in this segment. Based on the research findings, Frost & Sullivan expects 24 drugs will launch for the treatment of breast cancer in the U.S. between 2012 and 2017.
If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company Web site, city, state and country.
The U.S. breast cancer therapeutics market is divided into four segments, including hormonal therapy, targeted therapy, chemotherapy and other therapy (for example, novel drugs in development). While approximately 70 percent of breast cancers qualify for hormonal therapy, there are only roughly seven hormonal therapies on the market for the treatment of breast cancer.
“Despite the current drugs on the market, there remain a number of unmet needs in the U.S. breast cancer therapeutics market,” said Frost & Sullivan Life Sciences Global Program Manager Jennifer Brice. “For example, there are no antibody-based therapies approved for the treatment of breast cancer patients with low human epidermal growth factor receptor 2 (HER2) expression. In addition, the market is lacking HER2-targeted adjuvant treatment options to maintain disease-free status.”
The next drug expected to hit the market is Eli Lilly’s IMC-1121B, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody (MAb). This is a targeted treatment that identifies and attacks specific cancer cells without harming normal cells. In addition to VEGF, the only other targeted therapy is HER2-positive treatments. Of these two targeted therapy options, there are only two approved (non-antibody-based) treatments available in the U.S. market: Herceptin and Tykerb.
Market participants must ensure their breast cancer therapeutic treatments meet safety and regulatory stipulations. For example, Avastin (bevacizumab) was pulled from the market for treating advanced breast cancer due to safety risks. Additionally, targeted therapeutics for breast cancer can cause serious heart problems, such as heart attack, irregular heartbeats, decline in heart function, and in the most serious cases, death.
“Despite these safety concerns, treatment is a necessary function,” said Brice. “This is particularly true for those diagnosed with breast cancer, so they may maintain a disease free status and survival.”
A Product and Pipeline Analysis of the U.S. Breast Cancer Therapeutics Market is part of the Life Sciences Growth Partnership Service program, which also includes research in the following markets: Analysis of the United States Glaucoma Pharmaceuticals Market, Specialty Physicians Discuss their Opinions of the United States Biosimilars Market, Analysis of the United States Contract Manufacturing Outsourcing Market, Strategic Analysis of the U.S. Research Antibodies Market, and Analysis of the U.S. Clinical Laboratory Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation
A Product and Pipeline Analysis of the U.S. Breast Cancer Therapeutics Market
Contact:
Britni Myers
Corporate Communications North America
P: 210.477.8481
F: 210.348.1003
E: britni.myers@frost.com
SOURCE Frost & Sullivan
